Skip to main content

BROMHEXINE

 BROMHEXINE


BRAND NAME:- BROMHEXINE 8mg tablet,4mg/5ml elixer.

BROMHEXINE is a derivative of the alkaloids vasicine obtained from Adhatoda vasica (Vaska), is a potent mucolytic and mucokinetic , capable of inducing thin copious bronchial secertion.

PHARMACODYNAMIC:-
Bromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions .

MECHANISM OF ACTION:-
BROMHEXINE is a mucolytic agent that act on the mucus glands in the respiratory tract to change the structure of  bronchial secertion . It enhances the transport of  mucus by reducing its viscosity and increase cilia activity resulting in enhances mucocilliary clearance. This secretolytic and secretomotor effects in the bronchial tract  facilitates expectoration and relives  cough.

USED:-
Bromhexine is used in the treatment of respiratory tract disorders associated with viscid mucus. 

SIDE EFFECTS:-

Dizziness, Headache, Nausea, Upper abdominal pain, Vomiting, Diarrhea, Rash, Red spots or bumps, Itching, Sweating, Changes in serum aminotransferase levels

DOSE:- Adults 8mg TDS, children 1-5 years 4mg BD ,5-10yeras 4mg TDS. 
Labels:

Comments

Post a Comment

Popular posts from this blog

Cefpodoxime proxetil Uses, Side Effects, and More

 Cefpodoxime proxetil Brand name:- cefoprox ,cepodem,DOXCEF 100,200mg cap.  Cefpodoxime Proxetil is an antibiotic. It kills the bacteria by preventing them from forming the bacterial protective covering (cell wall) which is needed for them to survive. Pharmacodynamic:-  Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Mechanism of action:-  Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicilli
Post a Comment
Read more

Cephalexin ( ZYD ) ( Cefalexin ) Uses, Side Effects, and More

 Cephalexin (ZYD) (Cefalexin) Brand name:-  Cephacillin 250,500mg cap; Sporidex, Alcephin,Cephaxin cap. Cephalexin (also called Cefalexin)  is the most common used orally effective first generation cephalosporin , similar in spectrum to cefazolin , but less active against penicillinase producing staphylococci and H. Influenza. Plasma protein binding is low; it attains High concentration in bile and is excreted unchanged in urine; t½ - 60min. Pharmacodynamic:-  Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic. It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.Label It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis. Pharmacokinetics:- Cephalexin is rapidly and almost completely absorbed from t
Post a Comment
Read more

BASILIXIMAB Uses, Side Effects, and More

 BASILIXIMAB BRAND NAME:- Simulect   BASILIXIMAB is another anti CD - 25 antibody with higher affinity for the IL-2 receptor, but shorter plasma t½ (1 week) . is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection. PHARMACODYNAMIC:- Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.  MECHANISM OF ACTION:-  Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the trans
1 comment
Read more